Exact Sciences (EXAS) AI Stock Analysis

• Market Cap: $13.19B
• Dividend Yield: N/A
• Average Volume (3M): 2.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 14.47%
• EPS Growth: -353.69%
• Country: US
• Employees: 6,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.10
• Shares Outstanding: 189,471,300
• 10 Day Avg. Volume: 3,570,269
• 30 Day Avg. Volume: 2,555,293
• PEG Ratio: -0.03
• Price to Book (P/B): 4.31
• Price to Sales (P/S): 3.75
• P/FCF Ratio: 138.84
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 3.86
• Enterprise Value/Gross Profit: 5.73
• Enterprise Value/Ebitda: -15.96
• 1Y Price Target: $76.43
• Price Target Upside: 15.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18
• EPS Forecast (FY): -0.55
• Revenue Forecast (FY): $3.16B

• Rating: 62 Neutral
• Price Target: $71.00 ▲(7.28% Upside)

Exact Sciences' overall stock score is driven by strong technical indicators and positive earnings call highlights, including record revenue growth and successful product launches. However, the score is tempered by ongoing profitability challenges and a negative P/E ratio, indicating areas for improvement.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for Exact Sciences' products, enhancing its market position and supporting long-term business expansion.

Product Expansion

The launch of Cancerguard represents a strategic expansion into a large market, potentially driving future revenue and solidifying Exact Sciences' leadership in cancer diagnostics.

Medicare Coverage

Securing Medicare coverage for Oncodetect enhances accessibility and adoption, supporting sustained revenue growth and strengthening Exact Sciences' competitive advantage.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, highlighted by negative net income, may hinder Exact Sciences' ability to invest in growth and innovation, impacting long-term financial health.

Blood Test Performance

Underwhelming performance of blood-based tests may limit Exact Sciences' ability to capture market share in this segment, affecting future growth prospects.

R&D Challenges

Reliance on external technology for R&D indicates potential weaknesses in innovation capabilities, which could affect Exact Sciences' competitive edge in the long term.

Exact Sciences Business Overview & Revenue Model

Company Description

Exact Sciences Corporation is a molecular diagnostics company based in Madison, Wisconsin, primarily focused on the early detection and prevention of cancer. The company operates in the healthcare sector, specializing in non-invasive screening tests for colorectal and other cancers. Its flagship product, Cologuard, is a stool-based DNA test designed to detect colorectal cancer and precursors to the disease, while the company is also involved in developing tests for other types of cancers, enhancing its portfolio of oncology-focused diagnostic solutions.

How the Company Makes Money

Exact Sciences generates revenue primarily through the sale of its diagnostic tests, particularly Cologuard, which is reimbursed by various healthcare payers, including Medicare and private insurance providers. The company also earns revenue from laboratory services and partnerships with other healthcare organizations to expand its test offerings and reach. Significant partnerships, such as collaborations with pharmaceutical companies and healthcare systems, help enhance its market presence and contribute to its earnings. Additionally, Exact Sciences invests in research and development to innovate and broaden its test portfolio, aiming to capture more market share in the oncology diagnostics space.

Exact Sciences Financial Statement Overview

Summary

Exact Sciences shows moderate revenue growth and improving cash flow, which are positive indicators. However, challenges with profitability and return on equity persist, and the company needs to enhance operational efficiency and profitability to improve overall financial health.

Income Statement

Exact Sciences shows a moderate revenue growth rate of 4.83% TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The gross profit margin remains relatively strong at 68.19%, but the consistent net losses highlight ongoing challenges in achieving operational efficiency.

Balance Sheet

The company's debt-to-equity ratio of 1.02 TTM suggests a balanced approach to leveraging, but the negative return on equity indicates that the company is not generating sufficient returns on shareholders' investments. The equity ratio is not provided, but the overall leverage appears manageable, albeit with room for improvement in profitability.

Cash Flow

Exact Sciences has shown a significant improvement in free cash flow growth at 45.67% TTM, which is a positive sign. The operating cash flow to net income ratio of 0.59 indicates some efficiency in converting income to cash, though the free cash flow to net income ratio of 0.56 suggests that cash generation relative to net income could be better.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.08B	2.76B	2.50B	2.08B	1.77B	1.49B
Gross Profit	2.08B	1.92B	1.76B	1.42B	1.31B	1.14B
EBITDA	-744.67M	-789.33M	29.28M	-421.11M	-649.28M	-653.88M
Net Income	-986.58M	-1.03B	-204.15M	-623.51M	-595.63M	-823.61M
Balance Sheet
Total Assets	5.90B	5.93B	6.47B	6.23B	6.68B	4.93B
Cash, Cash Equivalents and Short-Term Investments	1.00B	1.04B	777.64M	632.06M	1.03B	1.84B
Total Debt	2.54B	2.75B	2.55B	2.45B	2.38B	2.33B
Total Liabilities	3.40B	3.53B	3.33B	3.18B	3.30B	2.69B
Stockholders Equity	2.50B	2.40B	3.15B	3.04B	3.39B	2.24B
Cash Flow
Free Cash Flow	247.08M	74.55M	31.93M	-438.02M	-238.00M	72.13M
Operating Cash Flow	386.81M	210.54M	156.12M	-223.56M	-102.24M	136.48M
Investing Cash Flow	62.13M	-442.15M	49.68M	74.07M	-1.08B	-702.04M
Financing Cash Flow	-251.72M	231.87M	159.77M	76.48M	8.47M	1.88B

Exact Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 66.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXAS, the sentiment is Positive. The current price of 66.18 is above the 20-day moving average (MA) of 63.93, above the 50-day MA of 58.09, and above the 200-day MA of 51.76, indicating a bullish trend. The MACD of 2.83 indicates Negative momentum. The RSI at 63.05 is Neutral, neither overbought nor oversold. The STOCH value of 50.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EXAS.

Exact Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	66 Neutral	$9.34B	23.23	11.29%	2.91%	5.32%	336.29%
CDNA	64 Neutral	$850.18M	12.59	24.11%	―	14.46%	―
EXAS	62 Neutral	$13.19B	―	-34.54%	―	14.47%	-353.69%
FLGT	57 Neutral	$697.27M	―	-4.54%	―	4.31%	69.57%
GH	54 Neutral	$11.98B	―	―	―	30.38%	24.17%
NEO	53 Neutral	$1.35B	―	-12.99%	―	10.10%	-44.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Exact Sciences Corporate Events

Exact Sciences Reports Record Q3 Revenue and Raises Guidance

Exact Sciences Corp., a prominent player in the cancer screening and diagnostics sector, continues to innovate with products like Cologuard® and Cancerguard, aiming to enhance early cancer detection and patient outcomes.

Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer

Study Overview: The EXActDNA-003 / NSABP B-64 study, officially titled ‘Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease,’ aims to explore the use of a circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD) in patients with high-risk early breast cancer. This study is significant as it seeks to improve recurrence prediction, potentially enhancing patient outcomes.

Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection

Exact Sciences Corp is currently recruiting participants for its study titled ‘Falcon – The Exact Sciences Multicancer Early Detection (MCED) Real World Evidence (RWE) Registry.’ The primary objective of this study is to gather real-world evidence on the performance of the Exact Sciences MCED test, which is significant for advancing early cancer detection methods.

Exact Sciences Corp’s Strong Earnings Call Highlights

Exact Sciences Corp’s recent earnings call showcased a robust performance, marked by impressive revenue and EBITDA growth. The company highlighted successful expansions and new coverage agreements, which are set to bolster future prospects. However, challenges such as underperformance in blood-based test results and restructuring costs were also noted, impacting the financial landscape.

Exact Sciences Corp. Reports Strong Q2 2025 Results

Exact Sciences Corp., a prominent player in the cancer screening and diagnostics sector, continues to innovate and expand its offerings, providing vital tools for early cancer detection and management.

Exact Sciences Announces Collaboration with Freenome Holdings

On August 6, 2025, Exact Sciences announced a collaboration with Freenome Holdings to develop blood-based colorectal cancer screening products. The company reported record second-quarter revenue of $811 million, a 16% increase from the previous year, and raised its full-year revenue and adjusted EBITDA guidance. Key achievements included gaining Medicare coverage for its Oncodetect test and launching a multi-year productivity plan targeting $150 million in savings by 2026.

The most recent analyst rating on (EXAS) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.